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Neurolymphomatosis (NL) is a rare clini-
cal entity. The International Primary CNS
Lymphoma Collaborative Group retro-
spectively analyzed 50 patients as-
sembled from 12 centers in 5 countries
over a 16-year period. NL was related to
non-Hodgkin lymphoma in 90% and to
acute leukemia in 10%. It occurred as the
initial manifestation of malignancy in 26%
of cases. The affected neural structures
included peripheral nerves (60%), spi-
nal nerve roots (48%), cranial nerves
(46%), and plexus (40%) with multiple
site involvement in 58%. Imaging stud-
ies often suggested the diagnosis with
77% positive magnetic resonance imag-
ing, and 84% (16 of 19) positive com-
puted tomography-positron emission
tomography studies. Cerebrospinal
fluid cytology was positive in 40%, and
nerve biopsy confirmed the diagnosis in
23 of 26 (88%). Treatment in 47 patients
included systemic chemotherapy (70%),
intra-cerebrospinal fluid chemotherapy
(49%), and radiotherapy (34%). Response to
treatment was observed in 46%. The median
overall survival was 10 months, with 12- and
36-month survival proportions of 46% and
24%, respectively. NL is a challenging diag-
nosis,butcontemporary imagingtechniques
frequently detect the relevant neural inva-
sion. An aggressive multimodality therapy
can prevent neurologic deterioration and is
associated with a prolonged survival in a
subset of patients. (Blood. 2010;115(24):
5005-5011)
Introduction
The term neurolymphomatosis (NL) encompasses nerve infiltration
by neurotropic neoplastic cells in the setting of an unknown or a
known hematologic malignancy. It is a rare neurologic manifesta-
tion of non-Hodgkin lymphoma (NHL) and leukemia with a poorly
defined incidence. The most comprehensive review identified
72 cases of NL caused by NHL that were reported during a 28-year
period.1 The majority of patients with NL described in the literature
had NHL; and in that setting, NL appears to represent a unique
subtype of extranodal disease. However, nerve-infiltrating disease
may occur rarely in leukemia2-4; therefore, the present study
assessed this clinical entity in patients with either NHL or
leukemia.
The typical manifestations of NL are of a neuropathy that may
affect peripheral nerves, nerve roots, plexus, or cranial nerves. The
most common presentations include painful peripheral neuropathy
or radiculopathy, cranial neuropathy, painless polyneuropathy, and
peripheral mononeuropathy or a mononeuropathy multiplex. Suc-
cessful therapy is contingent on the recognition of this unique
neurologic complication, yet the diagnosis is difficult and often
elusive. Because NL is rare, there is limited information available
on mode of presentation, clinical course, yield of diagnostic
procedures, and response to therapy. As well, the survival after
diagnosis and treatment is poorly characterized as it has never been
reported in a systematic study.
The International Primary Central Nervous System Lymphoma
Collaborative Group (IPCG) is a multidisciplinary group estab-
lished in 2002 under the sponsorship of the International Extra-
nodal Lymphoma Study Group. Given the rarity of NL, this
neurologic complication of lymphoma and leukemia was identified
as an area for which collaborative work could further our understand-
ing of the disease. We report a retrospective analysis of 50 cases of
NL that were assembled by 9 IPCG investigators from 12 centers in
5 countries. Because malignant infiltration of peripheral nerves
occurs in both NHL and leukemia, the current study investigated
both conditions under the common term of NL.
Methods
A retrospective chart review was conducted by the IPCG investigators to
collect information on HIV-seronegative adult patients whose final diagno-
sis was compatible with the definition of clinical neuropathy characterized
by infiltration of malignant lymphocytes. As this study is retrospective,
inclusion of patients was based on final diagnosis of NL that often required
the full perspective of the course of neurologic manifestations and the
related diagnostic workup. Eligible were patients with neoplasms catego-
rized as either lymphoma or leukemia. Other hematologic malignancies
were excluded. Eligibility criteria included patients whose clinical manifes-
tation was consistent with either a primary NL, defined as NL that is the first
manifestation of the hematologic malignancy, or patients with secondary
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NL, in which NL is a site of relapse or progression of a previously
diagnosed lymphoma or leukemia. In principle, NL was defined as
neuropathy that is characterized by infiltration of malignant cells. Yet,
manifestation of either cranial neuropathy or cauda equina involvement in
the presence of positive cytology was not considered as NL unless evidence
existed for intradural as well as extradural infiltration of the affected nerves
or, alternatively, additional data indicated that malignant infiltration of
either peripheral nerves and/or neural plexi has also developed. Malignant
infiltration of nerve structures that occurred in the setup of a bulky disease
that entrapped and infiltrated the neural elements was excluded. In primary
NL, infiltration of the affected neural structure had to be proved by a biopsy
or at autopsy. In secondary NL, the diagnosis required exclusion of other
causes of neuropathy, presence of positive imaging findings that detected
specific neural involvement, and evidence for disease progression. If
diagnosis remained in doubt, a biopsy of the affected structure was required
or otherwise autopsy findings indicated the final diagnosis.
A data collection form was sent to investigators, and each one received
ethics committee approval from all participating institutions for the release
of case information that was rendered anonymous. Requested information
included patient demographics, details of clinical history and presentation,
prognostic parameters such as Eastern Cooperative Oncology Group
Performance Status (ECOG-PS), serum lactate dehydrogenase level, dis-
ease stage, extranodal site(s) involved at the diagnosis of lymphoma,
International Prognostic Index (IPI) score, cell type or karyotype, and total
white blood cell count at diagnosis. Information was requested on
neurologic status (muscle weakness, sensory deficit, and autonomic abnor-
malities) as well as on the neurologic function5 at the diagnosis of NL. The
neurologic function was assessed according to the following scale:
0 indicates no neurologic symptoms (fully active at home/work without
assistance); 1, minor neurologic symptoms (fully active at home/work
without assistance); 2, moderate neurologic symptoms (fully active at
home/work but requires assistance); 3, moderate neurologic symptoms (less
than fully active at home/work and requires assistance); and 4, severe
neurologic symptoms (totally inactive requiring complete assistance at
home or in institution, unable to do work). Data were collected on
diagnostic measures conducted for evaluation of the neuropathy, including
imaging studies, cerebrospinal fluid (CSF) evaluation, and biopsy and DNA
analysis of body fluids or tissues. In addition, the form requested
information on types of treatment given for NL, response to treatment that
was evaluated by posttreatment ECOG-PS, neurologic function score,
neurologic status, and posttreatment imaging studies. Data on disease
progression, site(s) of involvement, and survival were reported.
Descriptive summaries included proportions for categorical variables
and medians, minimums, and maximums for numeric variables. Overall
survival was calculated from the date of diagnosis of NL to the date of
death. Surviving patients were censored at the date of last follow-up.
Survival curves were estimated using the Kaplan-Meier product-limit
methods,6 and comparisons between primary and secondary NL were
examined by the log-rank test.
Results
Information on a total of 50 patients was assembled. Patients with
NL were diagnosed from January 1993 to November 2008. During
this 16-year period, only 15 (30%) patients were diagnosed during
the first 8 years (until December 2000) and 35 patients were
diagnosed afterward with 50% of all cases identified after January
2004. Of the 11 cases diagnosed up to 1998, in 4 the final diagnosis
was established only at autopsy, whereas in all the rest diagnosis
was arrived antemortem. The increased rate of detection of NL
during the last 5 years raised the issue of whether the presumably
earlier or facilitated diagnosis is associated with changes in clinical
features and treatment outcome compared with those described
previously. Therefore, we present the main features of our series in
parallel to those enumerated in the English literature (Tables 1-2).
The literature search was conducted for reports of adult patients
with high-grade lymphoma or acute leukemia presenting with
cranial, spinal, or peripheral nerve infiltration by malignant cells of
these hematologic malignancies.
Table 1. Patient characteristics and clinical features of neurolymphomatosis
Characteristic
Group A: literature review with MGH
case series (1972-2000), N  72
Group B: literature review, case
reports (2001-2008), N  44
Group C: current IPCG case
series (1993-2008), N  50
Sex
Male 39 (54) 26 (59) 30 (60)
Female 33 (46) 16 (36) 20 (40)
Not reported 2 (4.5)
Median age, y (range) 63 (18-84) 56 (16-71) 55.5 (18-80)
NL as an extranodal site of systemic lymphoma 29 (40) 27 (61) 33 (66)
NL as the presentation of malignancy NA 13 (29.5) 13 (26)
Malignant cell type
B cells 59 (82) 29 (66) 41 (82)
T cells 4 (5) 11 (25) 5 (10)
NK cells 1 (2)
Not classified 9 (13) 3 (6.8) 4 (8)
Parenchymal brain involvement 19 (26) NA 11 (22), PCNSL
Affected neural structures*
Peripheral nerves 46 (64) 9 (20) 30 (60)
Spinal nerves 47 (65) 14 (32) 24 (48)
Neural plexus 23 (32) 15 (34) 20 (40)
Cranial nerves 37 (51) 15 (34) 23 (46)
Painful neuropathy 34 (47) 25 (57) 38 (76)
Type of neuropathy
Pure motor NA 7 (16) 11 (22)
Pure sensory NA 8 (18) 1 (2)
Sensorimotor NA 23 (52) 36 (72)
Not reported 6 (14) 2 (4)
Values are no. (%), except for age (y). Group A consists of a retrospective case series of 25 patients diagnosed in Massachusetts General Hospital (MGH) and literature
review of additional 47 cases that were published together.1 Group B is based on literature review.4,7-41 Group C is the current case series.
NA indicates not available; and PCNSL, primary central nervous system lymphoma.
*Involvement of multiple sites was common.
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Clinical features and diagnostic modalities
Patient characteristics are summarized in Table 1. The median age
of the current IPCG series was 55.5 years (range, 18-80 years) and
30 (60%) were males. The underlying malignancy was NHL in
45 (90%) patients and 5 had acute lymphoblastic leukemia. Of the
45 patients with NHL, 11 (24%) had initial diagnosis of primary
central nervous system lymphoma (PCNSL). The predominant
malignant cell type was B-cell; and of the 5 patients with T-cell
disease, 3 had acute leukemia. The most common subtype of
lymphoma was diffuse large B-cell (34 of 45; 75.5%). Four patients
had follicular lymphoma (9%), 2 peripheral T-cell lymphoma (4%),
and one mantle cell lymphoma (2%) and, in 4 cases (9%)
information on the subtype of the disease was not available.
NL occurred as the first manifestation of malignancy (primary NL)
in 14 (28%) cases (including 11 patients with systemic NHL,
2 with PCNSL, and 1 with leukemia) and as a relapse or progression of a
previously treated disease in the remaining 36 (23 patients with systemic
NHL, 9 with PCNSL, and 4 with leukemia). The 2 patients with primary
NL that initially were diagnosed as PCNSL presented with cranial
neuropathy as the initial manifestation of their disease. Cranial nerve
infiltration by malignant lymphocytes was proved by biopsy. Both were
then defined as PCNSL, but at disease progression they continued to
manifest features compatible with NL that included extension of neural
involvement beyond the dura matter. One patient also developed
parenchymal brain involvement during disease progression.
Secondary NL was diagnosed within a median interval of
10 months (range, 4-120 months) after initial diagnosis of the
hematologic malignancy. The median ECOG-PS at the diagnosis of
NL was 2. The IPI was reported in 32 of 34 (94%) patients with
systemic NHL, and 26 (81%) of them had intermediate to high IPI
(presence of 2 or more prognostic factors) at diagnosis.
NL affected more than one anatomic structure in 29 (58%)
patients (Table 1; Figure 1A-C). Peripheral nerves were the most
frequently involved site, whereas spinal, cranial nerve involve-
ment, and neural plexus infiltration occurred at a similar rate. The
manifestation of painful neuropathy was recorded in 38 (76%)
patients, with sensorimotor neuropathy being the most common
type (36 cases). Notwithstanding the infiltrative nature of NL, pure
motor neuropathy was described in 20% of the patients and pure
sensory neuropathy was noted in a single patient.
The diagnostic modalities included CSF analysis (in 45 pa-
tients), imaging studies that were reported for all patients, and
nerve biopsy that was obtained in 26 (52%) of the patients (Table
2). CSF analysis was remarkable for elevated protein in 61%, low
glucose level in 11%, and elevated cell count ( 5 cells/mm3) in
44%. Malignant cells were detected in the CSF in 18 (40%) of the
studies, and suspicious cytology was reported in another 6 (13%).
Of the 20 patients with elevated cell count, 12 had positive
cytology and 4 had suspicious cytology. Thus, 8 patients had
positive or suspicious cytology in the face of a normal CSF cell
count. Of patients with abnormal CSF cell count, in 6 (30%)
cases no cranial or spinal root involvement was evident. All the
rest manifested a combined affliction of cranial and/or spinal
roots together with plexus and/or peripheral nerves involve-
ment. The CSF evaluation also included polymerase chain
reaction–based gene rearrangement analysis of either the immu-
noglobulin heavy chain or of the T-cell receptor in 12 cases
(24%) and was positive in 4 (33%).
All patients were evaluated by imaging and 23 (46%) were
assessed by more than one modality. Magnetic resonance imaging
(MRI) was done in 47 (94%) cases whereas 18F-fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography–computed tomogra-
phy (PET-CT) was performed in 19 (38%) patients, the majority
(16; 84%) attained in patients diagnosed after 2004. The diagnostic
yield of MRI and FDG-PET was high (Table 2), with abnormal
findings found in 77% and 84%, respectively. MRI findings were
detailed in 41 of 47 (87%) patients and included abnormal
enhancement of the affected neural structure in 31 (76%) cases.
The affected nerves were most commonly characterized as thick-
ened (22 of 41; 53%), in 7 (17%) the involvement was diffuse, and
in 12 (30%) it was nodular. Despite the high yield of imaging
evaluation, the findings were often not definitive and consequently
nerve biopsy was performed in 26 (52%) patients. The biopsy
demonstrated NL in 23 (88%) patients. Biopsy was performed from
cranial nerves (2 cases), L2 spinal nerve root (1), brachial plexus
(1), and peripheral nerves (15), including sciatic, peroneal, sural,
femoral, and median nerves. Of the 5 sural nerve biopsies, 3 were
negative, whereas all other biopsies demonstrated neural infiltra-
tion by malignant cells. For 7 patients, the site of biopsy was not
specified.
Table 2. Diagnostic modalities and response to treatment of neurolymphomatosis
Diagnostic/treatment modality
Group A: literature review with MGH
case series (1972-2000), N  72
Group B: literature review, case
reports (2001-2008), N 44
Group C: current IPCG case
series (1993-2008), N  50
Imaging
CT NA 3/11 (27) 7/11 (64)
MRI 28/40 (70) 28/35 (80) 36/47 (77)
FDG-PET NA 19/21 (90) 16/19 (84)
CSF cytology 21/52 (40) 10/24 (42) 18/45 (40)
CSF PCR gene rearrangement NA 2/2 (100) 3/11 (27)
Biopsy of affected nerve 24/30 (80) 19/21 (90) 23/26 (88)
Diagnosis established only by autopsy 33 (46) 2 (5) 4 (8)
No. of patients treated for NL* 43 (60) 34 (77) 47 (94)
IV HD-MTX 5/43 (12) 8/34 (23.5) 23/47 (49)
Intra-CSF chemotherapy 15/43 (35) 14/34 (41) 23/47 (49)
Radiotherapy 10/43 (23) 17/34 (50) 16/47 (34)
Response rate† 31/43 (72) 20/34 (58) 16/35 (46)
Values are no. positive/no. of tests (%). Group A consists of a retrospective case series of 25 patients diagnosed in Massachusetts General Hospital (MGH) and literature
review of additional 47 cases that were published together.1 Group B is based on literature review.4,7-41 Group C is the current case series.
NA indicates not available; PCR, polymerase chain reaction; and IV HD-MTX, intravenous high-dose methotrexate.
*Some patients were treated by chemotherapy other than high-dose methotrexate.
†Includes complete and partial response by clinical improvement or by posttreatment imaging.
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Therapeutic management and outcome
Treatment was administered to 47 (90%) patients with NL (Table
2). Treatment varied, with systemic chemotherapy given to
33 (70%), intra-CSF chemotherapy to 23 (49%), and radiotherapy
in 16 (34%). Both intravenous and intra-CSF treatment was
administered to 19 (40%) patients, 4 (8.5%) received only intra-
CSF therapy, and 10 patients were managed by radiotherapy alone.
Systemic chemotherapy included high-dose methotrexate in
23 patients (given as monotherapy to 10 patients), high-dose
cytarabine in 18 patients (given as monotherapy to 5 patients), and
other combination chemotherapy in 5 cases (including 4 rituximab–
cytoxan, hydroxyrubicin, oncovin, prednisone combination). Intra-
CSF chemotherapy was administered by lumbar puncture or
through an intraventricular Ommaya device. This treatment was
given to 13 patients who manifested cranial and/or spinal root
involvement and to 11 patients who had high CSF cell count. Of the
23 patients who received intra-CSF chemotherapy, 11 (48%) were
treated with more than one agent. Intra-CSF chemotherapy in-
cluded cytarabine given to 17 patients, methotrexate in 14, and
3 patients were treated with rituximab.
Radiotherapy was delivered to symptomatic sites of NL;
however, 3 patients received a craniospinal field. Because of the
retrospective nature of this case series, data related to treatment
toxicity were inadequately reported.
The response to treatment was assessed by comparing the
pretreatment and posttreatment scores of ECOG-PS, neurologic
function score, report of neurologic status, and objective response
as detected by imaging. Of the 47 treated patients, pretreatment and
posttreatment evaluations were available as follows: ECOG-PS and
neurologic function in 35 patients, detailed neurologic status in 28
cases, and imaging in 25 patients. Response to treatment based on
35 pretreatment and posttreatment evaluations was noted in
16 (46%) patients who presented with a complete or partial
resolution of their symptoms and signs. An additional 9 (26%)
patients stabilized on treatment, and the remaining 10 patients
progressed despite treatment. The median ECOG-PS changed from
2 (pretreatment) to 1.5 (posttreatment) and median neurologic
function score from 2 to 1. These changes were not statistically
significant (paired t test). Posttreatment imaging demonstrated
complete resolution of the previously documented abnormalities
related to NL in 14 (56%) of 25 patients (Figure 1D-G), partial
response in another 3 (12%) cases, 1 patient showed no change, and
7 (28%) worsened. Objective response as demonstrated by imaging
corresponded to clinical and neurologic improvement in all 17
patients.
The overall median survival calculated from the diagnosis of
NL was 10 months (Figure 2A) with 12-month and 36-month
survival proportions of 46% and 24%, respectively. When survival
Figure 1. Imaging studies in NL. (A-B) FDG-PET imaging of a patient with neurolymphomatosis (NL). (A) Multiple sites of involvement, including the brachial and lumbosacral
plexi (arrows). (B-C) Bilateral involvement of the brachial plexus in the same patient clearly detected by both FDG-PET (B) and by MRI (C) T2 short T1 inversion recovery
imaging. (D-E) Enhanced MRI imaging (T1-weighted with gadolinium) of a patient with NL that affected multiple cranial nerves. (D) Bilateral abnormal enhancement of the
oculomotor nerves that corresponded to the clinical presentation of bilateral ophthalmoplegia. (E) Complete resolution of abnormal enhancement after 2 cycles of treatment
with intravenous high-dose methotrexate and intra-CSF treatment with cytarabine. These imaging findings matched the marked neurologic improvement observed under
treatment. (F-G) FDG-PET imaging of a patient with NL who presented with severe painful sensorimotor neuropathy and bilateral brachial plexus involvement. (F) FDG-PET
findings at diagnosis of NL compatible with bilateral brachial plexus involvement by lymphoma. (G) Complete resolution of abnormal tracer uptake after 2 courses of treatment
with systemic high doses of methotrexate and cytarabine. The treatments lead to clear neurologic improvement and good control of the painful neuropathy.
Figure 2. Survival of patients with NL. (A) Overall survival of the 50 patients from
the date of diagnosis of NL (median, 10 months). Vertical lines indicate censored
observations. (B) Survival of patients with either primary NL (median, 20 months;
13 patients) or secondary NL (median, 8 months; 37 patients). Vertical lines indicate
censored observations.
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of patients with primary NL was compared with survival of
secondary NL, no statistically significant difference was observed
(P  .129), although the median survival of the 13 patients with
primary NL was 20 months and that of secondary NL was 8 months
(Figure 2B).
Discussion
Diagnosis of NL requires integration of clinical presentation
(symptoms/signs), imaging findings, and pathologic data obtained
from neural, extraneural tissue, and the CSF. A high index of
suspicion and familiarity with the clinical manifestations of NL are
necessary. Because it is a rare manifestation of hematologic
malignancies, diagnosis is often delayed and its incidence remains
unknown.
The current series is the largest detailed series ever collected. It
describes the presentation, treatment, and outcome of 50 NL cases
that were diagnosed over a 16-year period (group C, Tables 1-2). A
previous literature review covered a 28-year period and identified
47 cases, which were reported together with 25 cases identified
retrospectively by the authors1 (group A, Tables 1-2). After this
publication, we found an additional 44 cases whose report was
published during an 8-year period (group B, Tables 1-2).
The majority ( 50%) of patients in the present report were
diagnosed in the last 5 years. This might be a product of an innate bias
linked with the retrospective nature of our series as more recent cases are
probably easier to identify and their records may be more accessible for
review. Alternatively, it may be related to an increased awareness of this
rare manifestation of lymphoma and leukemia or simply reflect a
facilitated diagnosis associated with the use of contemporary imaging
techniques. Lastly, it may signify a trend in the biologic behavior of
hematologic malignancies related to a selection of specific neurotropic
clones associated with either more aggressive treatment or longer
survival. To clarify whether any of the factors described might have had
an impact on our findings, we have tried to compare the current series
with previous publications (groups A and B). Group B corresponds to
the period of diagnosis of the greater fraction of our patients (group C).
Diagnostic modalities
Clinically, NL mimics non-neoplastic and paraneoplastic neuropa-
thies. Clinical findings that suggest NL, as opposed to remote
effects or inflammatory processes, include severe pain, asymmetric
distribution, and rapid evolution. Painful neuropathy predominated
in our series and was common in previously published cases (Table
1). Regardless, the diagnosis is elusive and in 46% of group A
patients (identified early in the time period studied), the precise
diagnosis was established only at autopsy. In the present case series
and in group B from the literature (Table 2), NL was more often
detected antemortem with diagnosis at autopsy reported in only
8% and 5% of cases, respectively. This phenomenon of a decrease
in the rate of postmortem diagnosis is probably related to the
improved resolution of current imaging techniques that can detect
affected neural structures with increased precision.
Of all diagnostic tools, imaging studies are of the greatest
clinical utility. All our patients were evaluated by one or more
imaging techniques, the majority (94%) by MRI. MRI reveals
nerve or root enlargement with or without contrast enhancement
and often involvement of neural plexus (brachial or lumbar) that is
more difficult to detect1,7-14 (Figure 1C). MRI findings are not
specific for NL and might sometimes be seen in acute or chronic
inflammatory radiculoneuropathies, in neurofibromatosis, in inflam-
matory pseudotumor, and in malignant tumors of the peripheral
nerve sheath. Interpretation of imaging studies in the context of
clinical manifestations and laboratory studies is necessary. MRI
yields abnormal findings in almost 80% of affected patients (Table
2) and facilitates the diagnosis, particularly when a history of
hematologic malignancy is known.
PET-CT appears to be a highly sensitive diagnostic method
facilitating identification of NL based on our experience and that
reported in the literature (group B, Table 2; Figure 1A,B,F).
Altogether, the reported experience is of 40 NL patients evaluated
by PET-CT, among whom 87.5% were positive studies. Although
the total number of reported cases diagnosed by PET-CT is still
small, positive findings are highly suggestive of the diagnosis of
NL, particularly in patients with a known history of hematologic
malignancy. Together with MRI findings, PET-CT may define the
best target for a biopsy, if one is indicated, especially in the instance
of primary NL.
Although the majority of our patients were evaluated by
multiple diagnostic modalities (Table 2), biopsy of an affected
nerve was indicated for pathologic confirmation in 52% of the
patients. The diagnostic yield of the biopsy was high (88%; Table
2) and was similar to the rate previously described in the literature
(groups A and B, Table 2). Therefore, if imaging and CSF findings
are inconclusive, a nerve biopsy presents a reasonable approach if
the risk does not outweigh the expected benefit.
Treatment and outcome
There is no known standard treatment for NL; therefore, optimal
management is ill defined. Treatment of NL consists of either
chemotherapy alone or combined with radiotherapy. To select the
appropriate therapy, knowledge of the extent of systemic and
nervous system involvement is essential. NL involves roots within,
as well as beyond, the borders of the subarachnoid space; thus,
intra-CSF chemotherapy and standard craniospinal radiation fields
will not treat all of the involved areas. Systemic chemotherapy is
critical to address the multiple sites of involvement.
In the current series, 90% of the patients were treated, a rate that
appears higher than that reported in the literature (groups A and
B, Table 2). This is probably related to the fact that our retrospec-
tive chart review specifically requested information on therapeutic
management. The information collected from the literature con-
tains inadequate information on clinical management as some of
the case reports addressed only the unusual neuroimaging
findings.8,11,14-21
In the current series, the majority of patients (70%) were
managed by systemic chemotherapy. The most effective regimen is
unknown, and the selection is often based on protocols used to treat
CNS involvement by malignant lymphoma. Many centers used
intravenous high-dose methotrexate, either alone or in combination
with other drugs and particularly with high-dose cytarabine.
Methotrexate is effective against lymphoma affecting the nervous
system and, when given in high doses, can penetrate the blood-
brain and blood-nerve barriers. Any other choice of chemo-
therapy must also meet those criteria. However, in our series,
approximately 30% of treated patients did not receive systemic
chemotherapy because NL represented relapse of a chemoresis-
tant disease.
Radiotherapy has a limited role in the treatment of NL resulting
from involvement of multiple sites, affecting both the CNS and the
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peripheral nervous system. Extensive radiation fields are poorly
tolerated in most patients, but limited-field radiotherapy can be
very effective in relieving unremitting neuropathic pain attributed
to a particular nerve, plexus, or nerve root.
Clinical improvement (functional recovery, reduction of pain)
and radiographic resolution (improvement of nerve root enlarge-
ment and enhancement or normalization of FDG-PET uptake) have
been observed in 50% to 70% of treated patients (Table 2; Figure
1D-G). Standardized criteria to measure response are not available;
therefore, no recommendations can be made regarding treatment
response.
There is no previous information on overall survival of patients
with NL. The median survival from diagnosis of NL in our series
was 10 months with 36-month survival proportion of 24%. These
data indicate that an aggressive multimodality therapeutic approach
can achieve long-term survival in some patients. The trend toward
longer median survival observed in primary NL probably reflects
the fact that NL was the presenting manifestation of the malignant
disease, unlike in secondary NL. Nonetheless, long-term survival
was observed in secondary NL, with 1 in 4 of all patients alive
at 3 years.
In conclusion, it appears that NL is more frequently diagnosed
in recent years. It is probably related to increased awareness of the
disease and an enhanced rate of diagnosis because of the extensive
use of contemporary imaging techniques that accurately localize
abnormal processes affecting neural structures. Early recognition
and treatment of this rare neurologic manifestation of lymphoma
and leukemia may improve outcome.
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